Withdrawn due to proactive dialogue
Resolution urging the Board of Directors to issue a report to shareholders by December 31, 2019, assessing the reputational and financial risks to Johnson & Johnson from rising pressure to reduce high prescription drug prices in the United States by removing barriers to generic competition.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.